Share
USER HOTLINE: call us at +49 30 65499 145 | Not all products are available in the USA.
Search for ""
Search for ""
CytoSorbents

Voices around the world

Our work has a significant impact: on patients and their families when lives are at risk, on healthcare professionals seeking options in critical moments, and overall, on advancing medicine by expanding the dimension of blood purification. Here are some global examples showcasing this impact.

Dr. Candido Amador

In my experience the vasopressor doses decreased, biomarkers of sepsis (…) and the inflammatory response as well as multiple organ function improved.

Search for Voices

About CytoSorbents Cardiovascular Critical Care Kidney Liver
Cardiovascular
Prof. em. Heinz Jakob
Essen, Germany

Listen to Dr. Heinz Jakob talk about his experiences with CytoSorb Therapy.

Kidney
Dr. Filipo Aucella
San Giovanni, Italy

When we started to use CytoSorb®, we were very impressed by the rapid decrease of myoglobin concentrations, and the renal damage also improved very rapidly.

Cardiovascular
Dr. Maria Grazia Calabro
Milan, Italy

CytoSorb is effective in reducing bilirubin, creatinine, and lactate in patients who are critically ill, mainly due to cardiogenic shock.

Critical Care
Dr. Tobias Hübner
Münsterlingen, Switzerland

The reason for us to use CytoSorb in the ICU was the lack of treatment options. We never had anything in sepsis, and CytoSorb® is the new star on the horizon.

Critical Care
Dr. Gabriella Bottari
Rome, Italy

We have applied CytoSorb in critical ill children with septic shock, with very good results.

Liver
Dr. Mihai Popescu
Bucharest, Romania

Our results show a potential benefit of CytoSorb in rebalancing liver function in patients with liver failure compared to MARS.

Cardiovascular
Dr. Serdar Gunaydin
Ankara, Turkey

One of the most important indications for us to use CytoSorb® in is cardiac surgery, as it has also been cited in many guidelines.

Critical Care
Dr. Willem Pieter Brouwer
Rotterdam, The Netherlands

Intervention with CytoSorb may be associated with decreased all-cause mortality at 28 days compared to continuous renal replacement therapy alone.

About CytoSorbents
Prof. Jean Louis Vincent
Brussels, Belgium

I would like to send my congratulations on the 10th anniversary of CytoSorb®. It is great how you have created a new way of blood purification therapy.

Critical Care
Juan Carlos Ruiz-Rodriguez
Barcelona, Spain

This case highlights that cytokine hemoadsorption can lead to a rapid decrease in IL-10 levels, and significant hemodynamic improvement was achieved.

Critical Care
Dr. Gabriella Bottari
Italy, Rome

Hemoperfusion with CytoSorb in combination with continuous kidney renal therapy is a valuable therapeutic option in sepsis-associated acute kidney injury.

Critical Care
Dr. Askhat Saparov
Astana, Kazakhstan

CytoSorb was safe and well-tolerated in a pediatric patient and has proven its value as an adjuvant therapy for sepsis in pediatric patient populations.

Critical Care
Prof. Peter Pickkers
Nijmegan, The Netherlands

The treatment with the CytoSorb® adsorber does reduce circulating concentrations at day one.

Critical Care
Dr. Abdulrahman Alharthy
Riyadh, Saudi Arabia

In this retrospective case series, CRRT with CytoSorb provided a safe rescue therapy in COVID-19 with associated AKI, ARDS, sepsis, and hyperinflammation.

Critical Care
Dr. Kai Singbartl
Phoenix, USA

The case represents the first successful application of CytoSorb in severe refractory neurotoxicity following treatment with chimeric-antigen-receptor T cells.

Cardiovascular
Dr. Henriette Roed-Undlien
Oslo, Norway

In this in vitro study, apixaban levels were effectively reduced, and the clotting time and thrombin generation assays were normalized by the use of CytoSorb.

Critical Care
Dr. Aleksandr Burov
Moskow, Russia

This case series demonstrates that combined blood purification therapy including CytoSorb may have a role for septic shock patients with primary brain injury.

Critical Care
Prof. JW Awori Hayanga
Morgantown, USA

In COVID-19 ARDS on VV-ECMO + hemoadsorption, 90-day survival 74% and early intervention associated with shorter organ support, supporting “enhanced lung rest”.

Cardiovascular
Dr. Haider Ghaidan
Lund, Sweden

CytoSorb restored lung function and reduced PGD in lung transplantation. We suggest this treatment will increase tolerability of donor lungs in recipients.

Critical Care
Dr. Pawel Piwowarczyk
Lublin, Poland

CytoSorb Therapy was able to facilitate long-term regain of balance between inflammatory process, cytokine production, and bilirubin turnover in the liver.

Critical Care
Dr. Anna Krakowiak
Lodz, Poland

In the event of poisoning with inorganic mercury compounds, CRRT using CytoSorb as an extracorporeal blood purification method may be considered.

Critical Care
Dr. Vanja Persic
Ljubljana, Slovenia

Use of CytoSorb in shocked SIRS patients was associated with rapid IL-6 decrease and hemodynamic improvement, with improved observed vs predicted survival.

Critical Care
Dr. Simao Rodeia
Lisbon, Portugal

Cytokine adsorption therapy with CytoSorb was employed with no direct complications, and helped control the inflammatory state.

Critical Care
Dr. Christopher Rugg
Innsbruck, Austria

Catecholamines decreased within 24 h after initiation of CytoSorb Therapy; in-hospital mortality was significantly lower in the CytoSorb group (35.7% vs 61.9%).

Cardiovascular
Perfusionist Anna Holmen
Gothenburg, Sweden

The accumulated norepi dose in the CytoSorb gp was half or less at all postop time points compared to controls..with significantly lower need for RBC.

Critical Care
Assoc. Prof. Berna Kaya Ugur
Gaziantep, Turkey

Use of CytoSorb achieved significant decreases in endocan, copeptin, IL-6, procalcitonin and C-reactive protein levels.

Kidney
Dr. John Ferdinand
Cambridge, UK

Our data suggest that adsorption of pro-inflammatory mediators from perfusate with CytoSorb represents potential intervention which may improve organ viability.

Liver
Prof. Dana Tomescu
Bucharest, Romania

The use of CytoSorb in patients with severe acute pancreatitis was associated with improved hemodynamics and decreased inflammatory markers.

Liver
Dr. Arosha Minori Gunasekera
Colombo, Sri Lanka

This patient with acute liver failure was managed successfully with supportive therapy, aided by CytoSorb hemoadsorption and therapeutic plasma exchange.

Cardiovascular
Dr. Endre Nemeth
Budapest, Hungary

Intraoperative hemoadsorption associated with better hemodynamics, lower post-op AKI and RRT, stable bilirubin, and shorter mechanical ventilation time and ICU

Critical Care
Dr. Fatime Hawchar
Szeged, Hungary

The first trial to investigate the effects of early extracorporeal cytokine adsorption treatment in septic shock applied without renal replacement therapy.

Kidney
Dr. Wun Fung Hui
Hong Kong, Hong Kong

Hemoadsorption with CytoSorb can be considered as an adjunctive therapy for children with severe rhabdomyolysis-associated acute kidney injury.

Critical Care
Dr. Maroua Eid
Angers, France

This case describes the successful use of CytoSorb with CRRT and extracorporeal life support in a combined way to overcome a critical phase of septic shock.

Critical Care
Dr. Marine Peyneau
France, Paris

CytoSorb appears to be safe and promising to fight post-lung transplantation inflammation, and should be re-evaluated in a larger study.

Cardiovascular
Dr. Daniel Lovric
Zagreb, Croatia

This is the first study showing an increase in urinary output and a trend towards better survival among patients on VA ECMO treated with CytoSorb.

Critical Care
Prof. Pedja Kovacevic
Banja Luka, Bosnia and Herzegovina

This case series describes potential positive effects of hemoadsorption in preventing the development of systemic hyperinflammation after vvECMO in ARDS.

Cardiovascular
Certified Clinical Perfusionist Martin Clerici
Buenos Aires, Argentina

Intraoperative use of CytoSorb® in an endocarditis patient with extensive cardiovascular history was associated with improvements in the hemodynamic situation.

Critical Care
Prof. Dorel Sandec
Timisoara, Romania

We treated more than 75 patients with CytoSorb® because we realized, we feel, we see, we measure a significant effect on the evolution of the patient.

Critical Care
Dr. Voyka Gorjup
Ljubljana, Slovenia

The most prominent clinical effect is the lowering of vasopressors, hemodynamic stability, lowering of interleukins and in those patients who are on vvECMO…

Critical Care
Dr. Candido Amador
Panama City, Panama

In my experience the vasopressor doses decreased, biomarkers of sepsis (…) and the inflammatory response as well as multiple organ function improved.

Critical Care
Assoc. Prof. Monir Sadat Hakemi
Tehran, Iran

It seems that applying the CytoSorb in combination with CRRT in ICU septic patients with AKI is correlated with a significant decrease in mortality.

Critical Care
Dr. Yatin Mehta
Gurgaon, India

CytoSorb is indicated for use in conditions where elevated levels of cytokine and/or bilirubin and/or myoglobin exist.

Cardiovascular
Dr. L. Christian Napp
Hannover, Germany

In the most critically ill patients on ECMO support, we observed a drop in catecholamine demand and an improvement in clinical state on ECMO.

Critical Care
Prof. Steffen Mitzner
Rostock, Germany

What strikes you first is that you can stabilize patients in septic shock.